Niealkoholowa choroba stluszczeniowa watroby jako nastepstwo ogolnoustrojowych zaburzen metabolicznych

• Autorzy: Tacikowski T , Dzieniszewski J. , Ciok J. , Godziemba-Maliszewska E.

Warianty tytułu

EN

Nonalcoholic fatty liver disease as a result of systemic metabolic disorders

• Języki publikacji: PL

Słowa kluczowe

PL

objawy chorobowe; stluszczenie watroby; stluszczeniowa choroba watroby niealkoholowa zob.stluszczenie watroby; stluszczeniowa choroba watroby zob.stluszczenie watroby; watroba stluszczeniowa zob.stluszczenie watroby; choroby czlowieka; otylosc; choroby watroby; cukrzyca; leczenie; etiopatogeneza; choroby metaboliczne

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2004
• Tom: 31
• Numer: 2
• Opis fizyczny: s.151-159,rys.,tab.,bibliogr.

Twórcy

autor

Tacikowski T

• Instytut Zywnosci i Zywienia, Warszawa

autor

Dzieniszewski J.

autor

Ciok J.

autor

Godziemba-Maliszewska E.

Bibliografia

• 1. Christoffersen E, Nielsen K.: Histologic changes in human liver biopsies from chronic alcoholics. Acta Pathol. Microbiol. Scand. (A), 1972, 80, 557, 21.
• 2. Lieber C. S., Jones D. E, Decarli L. M.: Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J. Clin. Invest. 1965, 44, 1009.
• 3. Sherlock S., Dooley J.: Nutritional and Metabolic Liver Diseases. In: Diseases of the liver and biliary system. Ed: S. Sherlock, J. Dooley. Oxford, Blackwell Eublishing, 2002, 426.
• 4. Ludwig J., Viggano T., McGill D. B., Ott B. J.: Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, 55, 434-438.
• 5. Allard J.P.: Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract. Res. Clin. Gastroenterol., 2002, 16, 783-795.
• 6. Schaffner F.: Nonalcoholic fatty liver disease. In: Progres in liver disease. Ed: F. Schaffner. London, Grune Stratton, 1986, 283.
• 7. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-92.
• 8. Boden G.: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997, 46, 3-10.
• 9. Fan C.Y., Pan J., Usuda N, et al.: Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acylCoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem., 1998, 19, 273, 15639-15645.
• 10. Caldwell S. H., Swerdlow R. H., Khan E. M., et al.: Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol., 1999, 31, 430-434.
• 11. Cortez-Pinto H., Chatham J., Chacko V. P., et al: Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. J. Am. Med. Assoc., 1999, 3, 282, 1659-1664.
• 12. Boden G.: Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5, 545-549.
• 13. Hotamisligil G. S., Peraldi P., Budavari A., et al.: IRS-l-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science, 1996, 2, 271, 665-668.
• 14. Tacikowski T., Milewski B., Dzieniszewski J., Walewska-Zielecka B.: Stluszczenie wątroby oceniane badaniem histopatologicznym u osób z hiperlipoproteinemią. Wiad. Lek., 1994, 47, 19-20, 731-737.
• 15. Tacikowski T., Dzieniszewski J.: Prevalence of Non-Alcoholic Hepatic Steatosis Depending on Overweight Degree in Individuals with Hyperlipoprote- inaemia. Adv. Clin. Exp. Med., 2001,10, 139-143.
• 16. Liu T. Y, Lu S. N., Su W. P., et al.: Prediction of fatty liver from serum triglyceride levels and body weight indexes. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih, 1990, 6, 289-294.
• 17. Tacikowski T., Dzieniszewski J., Rakoczy A., Tacikowska M.: Hipertrójglicerydemia jako niezależny od otyłości czynnik ryzyka rozwoju stłuszczenia wątroby u osób z hiperlipoproteinemią. Gastroenterol. Pol., 2001, 8, 143-147.
• 18. Assy N., Kaita K., Mymin D,. et al.: Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sei., 2000, 45, 1929-1934.
• 19. Heymsfield S. B., Greenberg A. S., Fujioka K., et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc., 1999, 282,1568-75.
• 20. Cinti S., de Matteis R., Ceresi E., et al.: Leptin in the human stomach. Gut, 2001, 49, 155.
• 21. Schwartz M. W., Woods S. C., Porte D., et al.: Central nervous system control of food intake. Nature 2000 404. 661-71.
• 22. Wilding J. P.: Neuropeptides and appetite control. Diabet. Med., 2002., 19, 619-27.
• 23. Song Y., Golling G., Thacker T.L., Cone R. D. : Agouti-related protein (AGRP) is conserved and regulated by metabolic state in the zebrafish, Danio rerio. Endocrine, 2003, 22, 257-65.
• 24. Marchesini G., Brizi M., Bianchi G., et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 2001, 50, 1844-1850.
• 25. Pagano G., Pacini G., Musso G., et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologie association. Hepatology, 2002, 35, 367-372.
• 26. Chitturi S., Abeygunasekera S., Farrell G. C., et al.: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.
• 27. Diehl A. M.: Nonalcoholic steatohepatitis. Semin. Liver Dis., 1999, 19, 221-229.
• 28. Clark J. M., Brancati F. L., Diehl A. M. E.: Nonalcoholic fatty liver diseases; the most common cause of abnormal liver enzymesin the U. S. population. Gastroenterology, 2001,120, A-65.
• 29. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
• 30. Luyckx F.H., Desaive C., Thiry A., et al.: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 222-226.
• 31. Harris M. I., Flegal K. M., Cowie C. C., et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U. S. adults. The Third National Health and Nutrition Examination Survey,1988-1994. Diabetes Care, 1998, 21, 518-524.
• 32. Program Pol-Monica. Warszawa. Kompleksowa ocena stanu zdrowia ludności Warszawy w roku 1993 i jego zmian w latach 1984-1993. Red: S. Rywik. Część V Instytut Kardiologii. Warszawa 1995.
• 33. Tacikowski T., Milewski B., Dzieniszewski J., i in.: Stłuszczenie wątroby oceniane badaniem ultrasonograficznym u osób z hiperlipoproteinemią. Wiad. Lek., 1994, 47, 19-20, 726-730.
• 34. Matsuura K., Tobe K., Tsuji T.: [Fatty liver and obesity in university students]. Nippon- Shokakibyo- Gakkai-Zasshi., 1995, 92, 1743-1751.
• 35. Osono Y., Nakajiama K., Hata Y.: Hypertriglyceridemia and fatty liver: clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemicpatients with fatty liver. J. Atheros. and Throm.,1995, 2, Suppl. S 47.
• 36. Lu S. N., Wang L. Y., Chang W. Y., et al.: Abdominal sonographic screening in a single community. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih., 1990,6, 643-646.
• 37. Doherty J. F., Adam E. J., Griffin G. E., Golden M. H.: Ultrasonographic assessment of the extent of hepatic steatosis in severe malnutrition. Arch. Dis. Child., 1992, 67, 1348-1352.
• 38. Suzuki K., Hayashi N., Sasaki Y., et al.: Evaluation of structural change in diffuse liver disease with frequency domain analysis of ultrasound. Hepatology,1993, 17, 1041-1046.
• 39. Yamasaki H., Tanemura M., Morimoto Y., et al.: [Study of postgastrectomy fatty liver].Nippon Geka Gakkai Zasshi,1992, 93, 1384-1389.
• 40. Saadeh S., Younossi Z. M., Remer E. M., et al.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123, 745-750.
• 41. Brallon A., Capron J. P, Herve M. A., et al.: Liver in obesity. Gut, 1985, 26, 133-139.
• 42. Evans C. D., Oien K. A., MacSween R. N., Mills P. R.: Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J. Clin. Pathol., 2002, 55, 689-692.
• 43. Dixon J. B., Bhathal P. S., O'Brien P. E.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 2001, 121, 91-100.
• 44. Bellentani S., Saccoccio G., Masutti F., et al.: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 18, 132, 112-117.
• 45. Marrero J. A., Fontana R. J., Su G. L., et al.: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.
• 46. Andersen T., Gluud C., Franzmann M. B., Christoffersen P.: Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 1991, 12,: 224-229.
• 47. Basaranoglu M., Acbay O., Sonsuz A.: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol., 1999, 31, 384.
• 48. Lavine J. E.: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr., 2000, 136, 734-738.
• 49. Marchesini G., Brizi M., Bianchi G., et al.: Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.
• 50. Laurin J., Lindor K. D., Crippin J. S., et al.: Ursodeoxycholic acid or Clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 1996, 23, 1464-1467.
• 51. Caldwell S. H., Hespenheide E. E., Redick J. A., et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 519-525.
• 52. Contos M. J., Cales W., Sterling R. K., et al.: Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl., 2001, 7, 363-733.
• 53. Charlton M., Kasparova P., Weston S., et al.: Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl., 2001, 7, 608-614.